Merck KGaA, AMCM/EOS co-operate in 3D printing of tablets27 Feb 2020
A cooperation agreement between German pharma firm Merck KGaA and additive manufacturing specialist AMCM on 3D printing of tablets could eventually lead to scalable active pharmaceutical ingredient (API) formulation and faster, cheaper production, the two companies said Thursday.
The pharma industry sees much potential in 3D printing technology as it offers potential solutions to the challenges around producing personalised medicines and tailored dosages. AMCM offers customized additive manufacturing solutions and is a sister company of 3D printing leader EOS.
The partnership will initially target GMP-compliant tablet formulation development and production for clinical trials before extending to commercial manufacturing services.
“Our partnership with AMCM/EOS could revolutionize the way tablets are produced. It will be a massive move towards digitalization of the industry,” said Isabel de Paoli, chief strategy officer at Merck. “Our goal is to develop the industrial application of this technology, which we will make available for clinical trials first, and then move to full digital solutions at commercial scale.”
Marie Langer, CEO of EOS said the co-operation combines Merck’s formulation and excipient expertise with AMCM's additive manufacturing know-how to "help make drug development more flexible and faster.”
The basis of the technology is using powder bed fusion methods -- whereby a laser melts and fuses powder together layer by layer -- to simplify the clinical development process of drugs, the firms said.
It is hoped that 3D printing will make API formulation scalable while avoiding costly reformulations throughout pharmaceutical development and commercial production processes.
According to the two companies, the vision is to achieve flexible and sustainable local tablet production that meets specific market requirements as well as adapting to patient needs.
A project teams at Merck's Innovation Center at its Darmstadt headquarters is working on next-generation tablet manufacturing through 3D printing.
New blood test able to detect 50 cancer types
31 Mar 2020
Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.Read more
European patent granted for amatoxin conjugates for tumor therapy
31 Mar 2020
The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.Read more
ProBioGen selected for development and large-scale manufacturing services
24 Mar 2020
The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.Read more
Positive update on the development of new XF‐platform drug formulations
24 Mar 2020
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.Read more
Alvotech and DKSH partner to bring key biosimilar to Asia
24 Mar 2020
Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.Read more
Codexis and Takeda collaborate to advance novel gene therapies
23 Mar 2020
Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.Read more
Vaxxas HD-MAP to deliver vaccines directly to the skin
17 Mar 2020
Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.Read more
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19
16 Mar 2020
The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.Read more
Technique improves drug delivery system characterization
16 Mar 2020
Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.Read more
Nanoform and Orion collaborate on 'nanoformed' APIs
9 Mar 2020
Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation